Subjects

Abstract

Programmed death 1 (PD-1)–deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance. We identify here PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4+ T cells. At low antigen concentrations, PD-L2–PD-1 interactions inhibit strong B7-CD28 signals. In contrast, at high antigen concentrations, PD-L2–PD-1 interactions reduce cytokine production but do not inhibit T cell proliferation. PD-L–PD-1 interactions lead to cell cycle arrest in G0/G1 but do not increase cell death. In addition, ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2, as compared to TCR ligation alone. PD-L expression was up-regulated on antigen-presenting cells by interferon γ treatment and was also present on some normal tissues and tumor cell lines. Taken together, these studies show overlapping functions of PD-L1 and PD-L2 and indicate a key role for the PD-L–PD-1 pathway in regulating T cell responses.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells>. Immunol. Rev. 165, 231–247 (1998).

  2. 2.

    & The emerging role of CTLA-4 as an immune attenuator. Immunity 7, 445–450 (1997).

  3. 3.

    et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA–4. Immunity 3, 541–547 (1995).

  4. 4.

    et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985–988 (1995).

  5. 5.

    , & Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7, 885–895 (1997).

  6. 6.

    , , & Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).

  7. 7.

    et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772 (1996).

  8. 8.

    , , & Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10, 1563–1572 (1998).

  9. 9.

    , , , & Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151 (1999).

  10. 10.

    et al. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science 291, 319–322 (2001)

  11. 11.

    , & Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J. Exp. Med. 191, 891–898 (2000).

  12. 12.

    , , & B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365–1369 (1999).

  13. 13.

    et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).

  14. 14.

    , & PD-1 inhibits B cell receptor-mediated signaling by recruiting SHP-2 to phosphotyrosine. J. Exp. Med. (Submitted, 2001).

  15. 15.

    , & Failure to suppress the expansion of the activated CD4 T cell population in interferon γ-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med. 192, 123–128 (2000).

  16. 16.

    et al. IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J. Immunol. 160, 2059–2064 (1998).

  17. 17.

    , & Regulation of antigen-specific CD8(+) T cell homeostasis by perforin and interferon-γ. Science 290, 1354–1358 (2000).

  18. 18.

    et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4(+) T cells. J. Immunol. 165, 5035–5040 (2000).

  19. 19.

    & CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533–2540 (1996).

  20. 20.

    , & CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183, 2541–2550 (1996).

  21. 21.

    et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J. Immunol. 162, 1270–1277 (1999).

  22. 22.

    , , , & Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332, 563–564 (1988).

  23. 23.

    et al. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc γRI and Fc γRIII binding. Immunology 86, 319–324 (1995).

  24. 24.

    , , & Selective induction of B7/BB-1 on interferon-γstimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell. Immunol. 137, 429–437 (1991).

Download references

Acknowledgements

Supported by a Wellcome Trust Travel Fellowship (to Y. L.) and National Institutes of Health grants AI38310, AI40614 (to A. H. S.) and AI39671, AI41584 and CA84500 (to G. J F.).

Author information

Author notes

    • Arlene H. Sharpe

    These authors contributed equally to this work.

Affiliations

  1. Immunology Research Division, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

    • Yvette Latchman
    • , Madhuri Borde
    •  & Arlene H. Sharpe
  2. Genetics Institute, Wyeth-Ayerst Research, Cambridge, MA 02140, USA.

    • Clive R. Wood
    • , Divya Chaudhary
    • , Andrew J. Long
    • , Karen Bourque
    • , Laura L. Carter
    •  & Beatriz M. Carreno
  3. Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

    • Tatyana Chernova
    • , Irene Chernova
    • , Julia A. Brown
    • , Raquel Nunes
    • , Edward A. Greenfield
    • , Vassiliki A. Boussiotis
    • , Nelly Malenkovich
    •  & Gordon J. Freeman
  4. Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.

    • Yoshiko Iwai
    • , Hiroyuki Nishimura
    • , Taku Okazaki
    •  & Tasuku Honjo

Authors

  1. Search for Yvette Latchman in:

  2. Search for Clive R. Wood in:

  3. Search for Tatyana Chernova in:

  4. Search for Divya Chaudhary in:

  5. Search for Madhuri Borde in:

  6. Search for Irene Chernova in:

  7. Search for Yoshiko Iwai in:

  8. Search for Andrew J. Long in:

  9. Search for Julia A. Brown in:

  10. Search for Raquel Nunes in:

  11. Search for Edward A. Greenfield in:

  12. Search for Karen Bourque in:

  13. Search for Vassiliki A. Boussiotis in:

  14. Search for Laura L. Carter in:

  15. Search for Beatriz M. Carreno in:

  16. Search for Nelly Malenkovich in:

  17. Search for Hiroyuki Nishimura in:

  18. Search for Taku Okazaki in:

  19. Search for Tasuku Honjo in:

  20. Search for Arlene H. Sharpe in:

  21. Search for Gordon J. Freeman in:

Corresponding author

Correspondence to Gordon J. Freeman.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/85330

Further reading